Skip to main content

A Phase 1 study of ublituximab and umbralisib in combination with targeted immunotherapy in patients with relapsed-refractory CLL or Richter's transformation of CLL

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

TG Therapeutics, Inc

Start Date

February 3, 2020

End Date

March 9, 2021
 

Administered By

Duke Cancer Institute

Awarded By

TG Therapeutics, Inc

Start Date

February 3, 2020

End Date

March 9, 2021